Albert Bourla said Pfizer committed about $2.3 billion to COVID vaccine development at once instead of in stages.
“Here, we put all together a little bit more than $2 billion, $2.3 billion.”
Person
Albert Bourla is the chief executive of Pfizer, and this page collects what he said on three podcasts: Lex Fridman Podcast, Freakonomics, M.D. and Conversations with Mike Milken. The talks mostly cover how Pfizer developed, tested, made and shipped its COVID-19 vaccine in 2020 and 2021.
On Freakonomics, M.D., Bourla said Pfizer made the vaccine in nine months, compared with about eight years normally. He told Lex Fridman that Pfizer asked its manufacturing teams to make 3 billion doses. He also talked about growing up in Thessaloniki, Greece, and about the reputation of the pharmaceutical industry.
3 episodes · 43 quoted claims
Albert Bourla said Pfizer committed about $2.3 billion to COVID vaccine development at once instead of in stages.
“Here, we put all together a little bit more than $2 billion, $2.3 billion.”
Albert Bourla said the 2009 Bextra case related to conduct that occurred in 2003.
“The Baxter case in 2009 was related to things that happened in 2003.”
Albert Bourla said the Bextra fine reflected the size of the product's revenues, not the severity of the conduct.
“the fine was related not to the severity of the conduct, but the size of the revenues.”
Albert Bourla said Pfizer narrowed about 20 candidate vaccines to four, then two, then one.
“We tried from 20 different vaccines, we nailed down to four. And for those four, we selected eventually two and then eventually one.”
Albert Bourla said Pfizer used 150 hospitals for trial recruitment instead of about 30 to speed enrollment.
“we had let's say 30 hospitals doing the recruitment we went with 150 hospitals doing the recruitment”
Albert Bourla said Pfizer's phase three COVID vaccine study cost almost a billion dollars.
“In our case, it costs almost a billion.”
Albert Bourla said the phase three trial was blinded, with placebo and vaccine looking identical to the people giving the injections.
“The placebo and the vaccine, they look identical. Nobody knows if it's injected a placebo or a vaccine.”
Albert Bourla said Pfizer's normal yearly vaccine production was about 200 million doses.
“our normal manufacturing yearly production of pfizer was 200 million doses of vaccines every year”
Albert Bourla said Pfizer asked its manufacturing teams to make 3 billion doses of the new vaccine.
“We asked them to make 3 billion doses for a new vaccine.”
Albert Bourla said discovering a new molecule normally takes four years, but Pfizer did it for its COVID pill in four months.
“The discovery phase of a new molecule, like the treatment that we have now, the pill against COVID, takes four years.”
Albert Bourla said Pfizer was producing roughly a billion vaccine doses per quarter, about four billion per year.
“Right now, we are running at 1 billion, almost, approximately, doses per quarter, four per year.”
Albert Bourla said Pfizer's employee vaccination rate rose from 90% to 96% after the company mandated vaccination.
“we were at 90 % vaccination rates when we said we are going to mandate it. And that took it up to 96%.”
Albert Bourla said Paxlovid is a five-day course of pills that cut hospitalizations from about 10 people to 1 in trials.
“you will take for five days pills, day and night, and twice a day for five days. and instead of 10 people from those that disease to go to hospital, only one will go.”
Albert Bourla said an independent Data Monitoring Committee unblinded the phase three data and told Pfizer whether the study succeeded.
“what we call the Data Monitoring Committee, which is a group of experts, independent experts”
Albert Bourla said the pharmaceutical industry's reputation over the previous decade was the lowest he had seen.
“It's clear that the reputation of the industry in the last decade was on the lowest that we have seen ever.”
Albert Bourla said some study results showed 100% efficacy, such as for deaths and in South Africa, but that such numbers fall as sample sizes grow.
“There were in the study things that were 100%, for example, deaths or in South Africa.”
Albert Bourla said Pfizer's scientists saw no reason ivermectin, a parasite drug, should work on COVID.
“I, as a scientist, and I discussed with our scientists, they don't see any reason why a medicine like ivermectin, which is a parasitic site, to be able to act on COVID.”
Albert Bourla said a false online story claimed his wife had died from vaccination, after an earlier false story claimed he was arrested by the FBI.
“A week later, the wife of the Pfizer CEO died.”
Albert Bourla says he was born and raised in Thessaloniki, the second-largest city in Greece.
“I'm Greek by nationality, so I was born and raised in the second largest city of Greece. It's called Thessaloniki.”
Albert Bourla says he chose to become a veterinarian at age 18 because he loved animals and medicine.
“I became veterinarian. I was 18 when I made the choice, and I had an immense love for animals, and I liked medicine.”
Albert Bourla says he lived in nine cities across five countries during his career with Pfizer.
“I lived in nine different cities of five different countries with Pfizer.”
Albert Bourla says that about 17 of his nearly 30 years at Pfizer were spent in its animal health group rather than its pharmaceutical group.
“Most of my career in the 30 years, I'm having 30 years next year, 17 of them was in the animal health group, not in the pharma group.”
Bourla says Pfizer was already working with BioNTech to develop an mRNA flu vaccine before choosing mRNA for COVID.
“we were working with this company, with BioNTech, to develop a flu vaccine for the rest of the years.”
Bourla says mRNA technology allows work to be done in weeks that takes months with other vaccine technologies.
“With mRNA, you can move extremely fast. You can do in weeks things that you take months with the other technologies.”
Bourla says adenovirus-based vaccines are harder to boost because the body also makes antibodies against the adenovirus carrier, which can reduce effectiveness.
“It's not easy to boost with adenovirus because every time you are boosting, you are not creating only antibodies against the coronavirus, but also against the adenovirus, which is the carrier.”
Bourla says mRNA vaccine manufacturing is not a biological production and can be adapted by swapping in new variants.
“You don't have some bacteria that they are making your vaccine eventually. So you can really plug and play in the mRNA.”
Bourla says an independent committee told Pfizer executives that the Phase 3 trial was successful in an interim analysis.
“They told us the news that it was successful in an interim analysis.”
Bourla says he was told the vaccine's efficacy in the interim analysis was 95.6.
“He said, so what is the efficacy? And then he told me 95.6.”
Bourla says that if the vaccine had failed, Pfizer would have written off $2.5 billion.
“one thing it is, okay, we failed, I will have to write off $2.5 billion.”
Bourla says he declined government funding because taking it would have required Pfizer's scientists to sit in numerous outside committees.
“by taking the money, I knew that my scientists will have to sit in numerous committees of people from wherever.”
Bourla says Pfizer's vaccine team met twice a week, with him making the final decision at those meetings.
“So I said, it's you and me. So we will all be meeting twice a week, everybody who is needy for a decision.”
Bourla says Pfizer made its COVID vaccine in nine months, compared with about eight years normally.
“if we were able to make a vaccine in nine months instead of eight years”
Bourla says Pfizer's clinical trial data showed only a very small percentage of patients with rebound symptoms after taking Paxlovid.
“We have looked into the data that we have in our clinical trial, and we saw a very small percentage of this occurring.”
Bourla says the reputation of pharmaceutical companies before the pandemic was as bad as that of government in polls.
“The reputation of the pharmaceutical companies was as bad as the reputation of government in polls.”
Albert Bourla says Pfizer is one of the world's biggest suppliers of injectable medicines to hospitals, providing more than a billion units per year.
“We are one of the biggest providers of injectables to hospitals in the world. We are providing one point something billion units every year in the world.”
Pfizer already had an agreement with BioNTech to develop mRNA technology, working on a flu vaccine, before they began their COVID-19 vaccine collaboration.
“we had already an agreement with BioNTech to work on this technology, and we were working with them on a flu vaccine.”
Pfizer's first shipment of finished vaccine left its Belgium manufacturing site for the United Kingdom, the first country to approve the product, within hours of approval.
“The first truck of finished goods left our Belgium manufacturing site and crossed the channel and drove to UK, which was the first country that approved the product, hours actually after the approval.”
Because Pfizer's vaccine requires two doses, 1.3 billion doses would protect 650 million people.
“This is a two-dose vaccine, which means that 1.3 billion doses will provide protection to 650 million people.”
Pfizer's COVID-19 vaccine had to be kept at minus 70 degrees Celsius before use.
“We had, in addition, to deal with the fact that our product needed to maintain in minus 70 degrees Celsius before it's going to be used in people.”
Pfizer engineers developed a suitcase-sized insulated shipping box carrying 1,000 to 5,000 vaccine doses with GPS and a thermometer.
“It is an isothermic box that can carry the size of a suitcase can carry from 1 ,000 to 5 ,000 doses and is equipped with GPS and the thermometer.”